Targeting IL-1α in cancer cachexia: a narrative review

Purpose of review Cachexia is defined as ongoing loss of skeletal muscle mass, with or without depletion of adipose tissue and is a common syndrome in cancer patients, affecting 50% of those diagnosed. Cachexia, which cannot be fully reversed and causes significant functional impairment is caused by various mechanisms such as an altered energy balance and disruption of homeostatic control by the central nervous system. This central nervous system deregulation involves hypothalamic pituitary adrenal (HPA) axis stimulation, which can be triggered by IL-1R1 engagement on neuronal processes and endothelium in the microvasculature of the hypothalamus. This review will explore current evidence regarding both the importance of IL-1α in the various components of cancer cachexia and its potential as a therapeutic target. Recent findings IL-1α, which signals through IL-1R1, has been identified as a key agonist in the IL-1 pathway. As such, IL-1α has been explored as a therapeutic target in cancer cachexia, leading to the development of bermekimab, a mAb which neutralizes IL-1α. With a limited array of medication currently available to treat cancer cachexia, bermekimab represents a possible therapy. Summary IL-1α is a key mediator in cachexia development and targeting this may be a viable therapeutic target.
Source: Current Opinion in Supportive and Palliative Care - Category: Palliative Care Tags: CACHEXIA, NUTRITION AND HYDRATION: Edited by Aminah Jatoi and Barry J.A. Laird Source Type: research

Related Links:

Authors: Singh G, Yoshida EM, Rathi S, Marquez V, Kim P, Erb SR, Salh BS Abstract Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide. If diagnosed early, curative treatment options such as surgical resection, loco-regional therapies, and liver transplantation are available to patients, increasing their chances of survival and improving their quality of life. Unfortunately, most patients are diagnosed with late stage HCC where only palliative treatment is available. Therefore, biomarkers which could detect HCC early with a high degree of sensitivity and specificity, may play...
Source: World Journal of Hepatology - Category: Gastroenterology Tags: World J Hepatol Source Type: research
Authors: Lundberg T, Forinder U, Olsson M, Fürst CJ, Årestedt K, Alvariza A Abstract The purpose of this study was to investigate variations in psychosocial well-being over time among young adults who participated in a support group after the death of a parent from cancer. Fifty-five young adults, aged 16-28 years, completed questionnaires that measured self-esteem, anxiety, depression, and life satisfaction at three time-points during the first year-and-one-half after the loss. Results indicated overall poor psychosocial well-being with few increases in psychological health over the study period,...
Source: Journal of Social Work in End-of-Life and Palliative Care - Category: Palliative Care Tags: J Soc Work End Life Palliat Care Source Type: research
CONCLUSION: while the evidence from the studies evaluating the use of massage therapy or the use of progressive muscle relaxation and guided imaging for the management of cancer pain in these patients demonstrated significant benefits, the other two studies that evaluated the use of acupuncture as a complementary therapy showed contradictory results, therefore, needing more research studies to elucidate such findings. PMID: 33027406 [PubMed - as supplied by publisher]
Source: Revista Latino-Americana de Enfermagem - Category: Nursing Authors: Tags: Rev Lat Am Enfermagem Source Type: research
When curative treatments are no longer available for cancer patients, the aim of treatment is palliative. The emphasis of palliative care is on optimizing quality of life and provided support for patients near...
Source: Health and Quality of Life Outcomes - Category: International Medicine & Public Health Authors: Tags: Review Source Type: research
Patients have a ‘need to know’ (instrumental need) and a ‘need to feel known’ (affective need). During consultations with patients with limited health literacy (LHL) in the palliative phase of their disease, b...
Source: BMC Palliative Care - Category: Palliative Care Authors: Tags: Research article Source Type: research
Authors: Mohan N, Edmonds KP, Ajayi TA, Atayee RS Abstract Tramadol is a schedule IV, monoaminergic and μ-opioid-receptor analgesic with unique pharmacology properties. Though it is well established and widely utilized, there is little guidance on tramadol's place in therapy, including tolerability, safety and monitoring guidelines. Retrospective chart review of 250 patients who received oral tramadol during their hospitalization from January 1, 2018 to December 31, 2018. Of the 250 patients, 10.8% had cancer as their primary diagnosis while 8.8% were admitted for hematologic reasons. 79.1% of patients had acute...
Source: Journal of Pain and Palliative Care Pharmacotherapy - Category: Palliative Care Tags: J Pain Palliat Care Pharmacother Source Type: research
Condition:   Advanced Lung Cancer Intervention:   Behavioral: Exercise, Nutrition, and Palliative Symptom Management Sponsors:   University of Calgary;   Tom Baker Cancer Centre Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Chronic opioid therapies (COT) are widely prescribed for the treatment of chronic pain related to palliative care, active cancer, and end-of-life care.43, 189 However, the use of COT to alleviate and manage chronic non-cancer pain (CNCP) remains controversial due to the risk for development of opioid use disorder, overdose, and opioid-related deaths.43 Despite the increased use of opioids to manage a wide range of chronic pain conditions, there is limited data regarding the effectiveness of long-term opioid treatment for CNCP particularly when considering COT as a primary treatment option.
Source: The Journal of Pain - Category: Materials Science Authors: Tags: Review Article Source Type: research
by Emilia Koz łowska, Rafał Suwiński, Monika Giglok, Andrzej Świerniak, Marek Kimmel We developed a computational platform including machine learning and a mechanistic mathematical model to find the optimal protocol for administration of platinum-doublet chemotherapy in a palliative setting. The platform has been applied to advanced metastatic non-small cell lung cancer (NSCLC). T he 42 NSCLC patients treated with palliative intent at Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, were collected from a retrospective cohort of patients diagnosed in 2004–2014. Patients were followe...
Source: PLoS Computational Biology - Category: Biology Authors: Source Type: research
We present a case of an advanced gastric cancer patient with chronic renal failure, who was treated with 5FU/leucovorin (LV) infusion chemotherapy (2-h infusion of LV and 5FU bolus followed by 46-h 5FU continuous infusion on day 1; repeated every 2  weeks) and developed hyperammonemia, with the aim of exploring an appropriate hemodialysis (HD) schedule to resolve its symptoms.MethodsThe blood concentrations of 5FU and its metabolites, α-fluoro-β-alanine (FBAL), and monofluoroacetate (FA) of a patient who had hyperammonemia from seven courses of palliative 5FU/LV therapy for gastric cancer were measured by l...
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Neurology | Nutrition | Palliative | Palliative Care